![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche Signs $1.7 Billion Deal with Blueprint Medicines to Develop Cancer Treatment
Roche Signs $1.7 Billion Deal with Blueprint Medicines to Develop Cancer Treatment
July 15, 2020
Roche has signed a $1.7 billion agreement with Blueprint Medicines to develop and commercialize Blueprint’s pralesetinib for treatment of patients with RET-altered cancers.
Blueprint and Roche’s subsidiary Genentech will co-commercialize pralsetinib in the U.S., while Roche will have exclusive rights to the drug outside of the U.S., except for China.
Blueprint will receive $775 million in upfront payments, and is eligible to receive up to $926 million in potential milestones, as well as royalties on sales outside of the U.S.
Upcoming Events
-
21Oct